Day: February 25, 2025

TopBuild Reports Fourth Quarter and Year-End 2024 Results, Provides 2025 Outlook and Announces New $1 Billion Share Repurchase Authorization

Written by Customer Service on February 25, 2025. Posted in Earnings Releases And Operating Results.

Fourth Quarter HighlightsFourth quarter sales grew 2.0% to $1.31 billion, driven by 6.6% improvement in Specialty DistributionDelivered gross margin of 29.9% and adjusted EBITDA margin of 19.7% Full Year HighlightsAchieved record 2024 results: sales of $5.3 billion and adjusted EBITDA of $1.07 billionCompleted 8 acquisitions totaling $153.1 million in annual salesReturned $966.4 million in capital to stockholders through the repurchase of ~2.5 million shares 2025 OutlookAnticipates full year 2025 sales between $5.05 to $5.35 billion and adjusted EBITDA in the range of $925 million to $1.075 billionAcquisitions continue to be top priority for deploying capital DAYTONA BEACH, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) — TopBuild Corp. (NYSE:BLD) a leading installer and specialty distributor of insulation and building material products...

Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance

Written by Customer Service on February 25, 2025. Posted in Earnings Releases And Operating Results.

PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023.GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023.Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023.Full-Year 2024Reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and a decrease of 1.3% on an organic basis compared to full-year 2023.GAAP earnings per diluted share were $(0.09), compared to $0.84 in 2023.Adjusted...

FLSmidth to deliver 18 of the world’s largest steel media tower mills, plus pumps and cyclones to one of largest and most efficient iron ore plants

Written by Customer Service on February 25, 2025. Posted in Public Companies.

PRESS RELEASE 25 February 2025, Copenhagen, Denmark Following a long-standing relationship, an Indian mining customer has awarded FLSmidth with the largest single order for the world’s largest size steel media tower mills. The mills are to be delivered at what is set to become one of the largest and most efficient iron ore beneficiation plants globally, reinforcing FLSmidth’s global leadership in energy-efficient grinding technology. The order includes the delivery of 18 vertical tower mills (called FTM-5000) to be used in both the secondary and tertiary grinding circuits, directly downstream from two of the world’s largest high-pressure grinding rolls (HPGRs), which the customer ordered from FLSmidth in Q4 2024. Each of these vertical grinding mills will be the largest steel media mills ever deployed in terms of both size and capacity....

Orion Group Financial Statement Release January–December 2024

Written by Customer Service on February 25, 2025. Posted in Earnings Releases And Operating Results.

ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2024 25 FEBRUARY 2025 at 12:00 EET Orion Group Financial Statement Release January–December 2024Net sales totalled EUR 1,542.4 (January–December 2023: 1,189.7) million Operating profit was EUR 416.6 (274.9) million Basic earnings per share were EUR 2.35 (1.54) Cash flow from operating activities per share was EUR 2.09 (0.85) The Board of Directors proposes a dividend of EUR 1.64 (1.62) to be paid for 2024. The dividend is proposed to be paid in two instalments. Outlook for 2025: Net sales are estimated to be EUR 1,550 million to EUR 1,650 million. Operating profit is estimated to be EUR 350 million to EUR 450 million.Key figures 10–12/24 10–12/23 Change % 1–12/24 1–12/23 Change %Net sales, EUR million 434.4 321.1 +35.3% 1,542.4 1,189.7 +29.6%EBITDA, EUR million 147.1 106.0 +38.8% 509.4 326.4 +56.0%%...

AKVA group ASA: Key information relating to cash dividend

Written by Customer Service on February 25, 2025. Posted in Public Companies.

Reference is made to the stock exchange announcement made by AKVA group ASA on 14 February 2025 regarding the financial results for the fourth quarter of 2024 and the resolution by the Board of AKVA group ASA to distribute a dividend of NOK 1.00 per share in the first half year of 2025, in total NOK 36,309,017. The dividend has been resolved on the basis of the Board’s authorisation as granted by the annual general meeting of AKVA group ASA on 2 May 2024. Key information relating to the cash dividend: Dividend amount: NOK 1.00 per share Announced Currency: NOKLast Day Inclusive: 7 April 2025 Ex-Date: 8 April 2025 Record Date: 9 April 2025 Payment Date: On or about 15 April 2025 Date of Approval: ...

Nokia, Vodafone and RingCentral to showcase future of voice calls at Mobile World Congress #MWC25

Written by Customer Service on February 25, 2025. Posted in Public Companies.

Press ReleaseNokia, Vodafone and RingCentral to showcase future of voice calls at Mobile World Congress #MWC25Immersive Voice and Audio Services (IVAS): The most significant advancement in voice-call audio technology in decades, will be jointly presented by Nokia, Vodafone and RingCentral highlighting the latest 5G Advanced audio capabilities. The joint demonstration underscores the partners’ intention to bring future IVAS-enabled calling experiences to a broad customer base.25 February 2025Espoo, Finland – Nokia today announced it is working with Vodafone and RingCentral to showcase Immersive Voice and Audio Services (IVAS) – the future of voice communication, providing users with a natural, three-dimensional sound experience even when calling from a remote location. The joint demonstration on the Vodafone booth at MWC 2025...

Municipality Finance issues EUR 15 million notes under its MTN programme

Written by Customer Service on February 25, 2025. Posted in Public Companies.

Municipality Finance PlcStock exchange release 25 February 2025 at 10:00 am (EET) Municipality Finance issues EUR 15 million notes under its MTN programme Municipality Finance Plc issues EUR 15 million notes on 26 February 2025. The maturity date of the notes is 26 February 2036. MuniFin has a right, but no obligation, to redeem the notes early on 26 February 2026. The notes bear interest at a fixed rate of 3.51% per annum until 26 February 2026, after which the interest is paid at 3.25% per annum, unless MuniFin redeems the notes early. The notes are issued under MuniFin’s EUR 50 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and the final terms of the notes are available in English on the company’s website at https://www.kuntarahoitus.fi/en/for-investors. MuniFin...

Rocket Doctor Approved as In-Network Provider for New York Medicaid, Expands Partnership with EngageWell to Enhance Care

Written by Customer Service on February 25, 2025. Posted in Public Companies.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Approval as an In-Network Provider for New York Medicaid Strengthening Access to Virtual Healthcare Across the State and Collaboration with EngageWell.Approved as an in-network provider for New York Medicaid, covering 6.9 million individuals (35% of the state’s population) Expands Rocket Doctor’s virtual healthcare services to Medicaid beneficiaries across New York Supports patients with urgent, primary, and specialty care via an advanced telehealth platform Service is designed to reduce ER visits, decrease wait times, and improve access to timely specialist referrals Advances Rocket Doctor’s mission to eliminate barriers to high-quality healthcare Partnership with EngageWell to enhance virtual care and support for aging New Yorkers...

Innofactor wins contract to provide the case and document management system for Gävle Municipality

Written by Customer Service on February 25, 2025. Posted in Public Companies.

Innofactor Plc press release February 25, 2025, at 10:00 Finnish time Gävle Municipality is taking an important step towards making the management of documents and cases both simpler and more efficient. Through a carefully conducted procurement process, the municipality chose Innofactor Dynasty, gaining a system that is not only easy to use but also simplifies everyday life for both employees and citizens. The new system will streamline case management, making everything from saving documents and opening new cases to meeting management more efficient. With clear roles and responsibilities, stability and security are created, contributing to a well-functioning and reliable administration. Additionally, Innofactor’s experts will be available to provide professional service and support, focusing on high quality. “With our extensive experience...

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Written by Customer Service on February 25, 2025. Posted in Public Companies.

STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the GOAL-HF1 clinical study. The study will evaluate AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction. Study results from GOAL-HF1 are expected by the end of the year. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure. The company´s lead asset, AC01, is currently being evaluated in a clinical phase 1b/2a study, GOAL-HF1, in patients with heart failure and reduced ejection fraction (HFrEF). The phase 2a part of the GOAL-HF1 study is randomized, double-blind and placebo-controlled, aiming to evaluate the safety, tolerability, pharmacokinetics...

Day: February 25, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals